Introduction {#s1}
============

Despite a recent decrease in the incidence of gastric cancer (GC) [@pone.0073683-Bertuccio1], it remains a cause of major morbidity and mortality worldwide, especially in Eastern Asia. A total of one million new cases of GC occurred in 2008, with 738,000 deaths [@pone.0073683-Jemal1]. This accounts for 8% of the total cases of cancer and 10% of total deaths. Although endoscopy can detect the early stages of GC, most cases are still diagnosed at an advanced stage, which results in a poor prognosis [@pone.0073683-Ang1]. The 5-year survival rate for GC cases with stage II ranges from 30% to 50%, but falls to between 10% and 25% for patients with stage III disease [@pone.0073683-Whrer1]. Although endoscopic techniques are developing rapidly, their value for the early detection of GC is limited due to a lack of sensitivity, high costs and inconvenience. New diagnostic and prognostic biomarkers for GC are therefore urgently required.

MicroRNAs (miRNA) are short noncoding RNA molecules of 19--25 nt. They regulate gene expression at the post-translational level by guiding the RNA-induced silencing complex to miRNA target sites in the 3′ untranslated region of mRNA, leading to mRNA degradation or the inhibition of translation [@pone.0073683-Gartel1]. Previous studies have shown that numerous miRNAs are aberrantly expressed in many kinds of cancers, and miRNA expression profiling has shown certain miRNAs to be associated with tumor development, progression and response to therapy. They are therefore good candidates for using as diagnostic, prognostic and predictive biomarkers [@pone.0073683-Iorio1].

Several studies have been conducted to search for biomarkers by identifying the differential expression of miRNAs between GC tissue samples and corresponding non-tumor gastric tissue from the same patient [@pone.0073683-Saito1]--[@pone.0073683-Guo1]. These studies have resulted in the identification of hundreds of differentially expressed miRNAs. However, many of these are likely to be false positives, and only a small fraction could be used as diagnostic or prognostic biomarkers. A logical approach to distinguish important miRNAs from a large number of candidate miRNA lists is to search for the intersection of miRNAs identified in multiple independent studies [@pone.0073683-Ma1]. Although this method has become increasing popular [@pone.0073683-Ma1], [@pone.0073683-Chan1], [@pone.0073683-Griffith1], no published study has identified the intersections of GC-related miRNAs based on a large number of miRNA expression profiling studies.

We conducted this systematic review to identify the most important differentially expressed miRNAs that have been consistently reported in a series of independent miRNA expression profiling studies in GC patients. Moreover, we further validated some of the miRNAs that were most up- or downregulated using real-time PCR in 32 pairs of GC and matched adjacent non-tumor tissue samples.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

The study was approved by the ethics committee of Shanghai Jiaotong University School of Medicine, and written informed consent was obtained from all patients at study entry.

Search Strategy {#s2b}
---------------

Potential studies published in English were collected from Medline using the following keywords: 'miRNA' OR 'microRNA' OR 'miR', 'gastric' OR 'stomach', 'profiling' OR 'microarray'. Lists of references of review articles and original articles were searched manually for additional publications.

Inclusion Criteria of the Literature {#s2c}
------------------------------------

For a study to be included in this systematic review, several criteria had to be met: 1) studies had to be miRNA profiling studies in GC patients; 2) studies had to use GC tissues and their corresponding adjacent non-tumor tissues for comparison; 3) methods had to comprise miRNA microarray techniques. Furthermore, only full-text publications in English were included. The profiling studies that used GC cell lines or serum samples from GC patients, those that compared GC biopsies from tumors with different stages of disease, and those that used different miRNA technologies were not included. Review articles were also not included in this systemic review.

Data Extraction and Lists of miRNA {#s2d}
----------------------------------

Differentially expressed miRNAs were identified from each included profiling study. Relevant information was determined (i.e., chromosomal location, pre-miRNA length, mature miRNA sequence and potential targets of the miRNAs), and missing information was identified from the miRBase database (www. mirbase.org/) and Pubmed.

Ranking {#s2e}
-------

Each included profiling study [@pone.0073683-Saito1]--[@pone.0073683-Guo1] provided a list of differentially expressed miRNAs ([Table S1](#pone.0073683.s001){ref-type="supplementary-material"}). Griffith and Chan devised a method to rank potential molecular biomarkers for comparison groups [@pone.0073683-Chan1], [@pone.0073683-Griffith1], which has been used for miRNA profiling studies. For example, Ma et al. [@pone.0073683-Ma1] identified the intersections of colorectal cancer-related miRNAs based on a large number of miRNA profiling studies. Thus, the criteria for the literature included in this current systematic review were based on those in their reports [@pone.0073683-Ma1]. MiRNAs were ranked to the criteria in the following order of importance: (i) the miRNA was consistently reported as differentially expressed in a consistent direction of change; (ii) the frequency of the miRNA was reported in the microarray studies; (iii)the total sample size for each consistent reported miRNAs.

Validation of the miRNAs Using Real Time PCR {#s2f}
--------------------------------------------

To validate the profiling results, 32 fresh GC tissues and their paired non-tumor gastric tissues were obtained from the Renji Hospital, affiliated to the Shanghai Jiaotong University School of Medicine. Total RNA was extracted from 32 pairs of matched human GC specimens (including cancer and adjacent noncancerous tissues) using TRIzol reagent (Invitrogen). The RNA concentration and purity was measured using Nanodrop ND-2000, and the ultraviolet absorption measurement method was applied to detect the purity of the RNA, only those A260/A280 located between 1.80--2.00, and A260/A230\>1.7, were used for the final experiment, otherwise the RNA must be re- extracted. Reverse transcription from 3 µg RNA was done usingAll-in-OneTM First-Strand cDNA Synthesis Kit(Genecopoeia, Guangzhou, China), according to the manufacturer's protocol. In brief, the prepared RNA reverse transcription reaction solution was incubated at 37°C for 60 minutes and terminated at 85°C for 5 minutes, and then stored at −20°C for further analysis. Quantitative PCR (qPCR) was performed using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, USA) with SYBR Premix Ex Taq II (Takara). The primers (miR-21-5p, miR-106b-5p, miR-17-5p, miR-18a-5p, miR-20a-5p and miR-378-5p) including U6 were obtained from Genecopoeia (Guangzhou, China). Quantification was calculated using the 2 −ΔΔCT method and is presented as normalized pattern.

Statistical Analysis {#s2g}
--------------------

The results were analyzed using SAS 9.2 software (SAS Institute Inc. USA). Data are presented as means ± SD. Student's t-test was used to compare values between two independent groups.

Results {#s3}
=======

Literature Selection and Study Characteristics {#s3a}
----------------------------------------------

A total of 104 studies were searched in Pubmed using our search strategy, 73 of which were excluded after screening the titles and abstracts. 23 studies were excluded after reading the full text. Only eight studies were finally included in this systematic review. The detailed study selection was shown in [Figure 1](#pone-0073683-g001){ref-type="fig"}. The detailed characteristics of each study are given in [Table 1](#pone-0073683-t001){ref-type="table"}.

![Flowchart of the study selection.](pone.0073683.g001){#pone-0073683-g001}

10.1371/journal.pone.0073683.t001

###### The characterestics of the eight microRNA profiling studies included in this systemic review.

![](pone.0073683.t001){#pone-0073683-t001-1}

  Study                                           Year                  Platform                   Total samplesize   No. of differentialmiRNAs   Up-regulatedmiRNAs in GC   Down-regulatedmiRNAs in GC
  ---------------------------------------------- ------ ----------------------------------------- ------------------ --------------------------- -------------------------- ----------------------------
  Saito et al [@pone.0073683-Saito1]              2012              Toray Industries                      20                     10                          NR                          10
  Wang et al [@pone.0073683-Wang1]                2012       miRCURY LNA microarray platform              6                      18                          NR                          18
                                                                    (Exiqon, Denmark)                                                                                       
  Oh et al [@pone.0073683-Oh1]                    2011     Agilent Human miRNA microarray(V2)             80                     80                          40                          40
  Ding et al [@pone.0073683-Ding1]                2010         µParaflo™ microfluidic chip                12                     15                          8                           7
                                                                 (LC Sciences, TX, USA)                                                                                     
  Tchernitsa et al [@pone.0073683-Tchernitsa1]    2010   NCODE muti-species microarray probe set          12                     22                          20                          2
                                                                  (Invitrogen, CA, USA)                                                                                     
  Ueda et al [@pone.0073683-Ueda1]                2010    Ohio State University custom microRNA          320                     35                          22                          13
                                                                     microarray chip                                                                                        
  Yao et al [@pone.0073683-Yao1]                  2009         miRCURY LNA array (V 11.0)                 6                      24                          22                          2
  Guo et al [@pone.0073683-Guo1]                  2008         µParaflo™ microfluidic chip                6                      19                          12                          7
                                                                 (LC Sciences, TX, USA)                                                                                     

Differentially Expressed miRNAs {#s3b}
-------------------------------

A total of 223 differentially expressed miRNAs were reported in the eight microarray studies (Differentially expressed miRNAs in each study were detailed in [Table S1](#pone.0073683.s001){ref-type="supplementary-material"}); 124 were upregulated in GC, and 99 were downregulated. Among the 223 differentially expressed miRNAs, 48 were reported in at least two studies; 39 (81.3%) had a consistent direction and nine (18.7%) had an inconsistent direction of altered expression. Among the former 39, 20 were upregulated in GC, and 19 were downregulated. Three of these miRNAs were reported in five microarray studies (miR-21, miR-106b and miR-378), four were reported in four studies (miR-17, miR-18a, miR-20a and miR-638), and seven were reported in three studies (miR-19a, miR-20b, miR-25, miR-30d, miR-923, miR-375, and miR-148a). Their chromosomal locations, pre-miRNA lengths, mature sequences and the potential targets are listed in [Tables 2](#pone-0073683-t002){ref-type="table"}--[4](#pone-0073683-t004){ref-type="table"}.

10.1371/journal.pone.0073683.t002

###### Up-regulated miRNAs (n = 20) reported in at least two expression profiling studies.

![](pone.0073683.t002){#pone-0073683-t002-2}

  miRNAsname    Chromosomallocalization   Pre-miRNAlength          Mature sequence                                                            Studies(reference)                                                      Total samplesizes       Potential Target
  ------------ ------------------------- ----------------- ------------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------------- ---------------------------
  miR-21                17q23.1                 72          8-uagcuuaucagacugauguuga - 29   5 [@pone.0073683-Oh1], [@pone.0073683-Ding1], [@pone.0073683-Tchernitsa1], [@pone.0073683-Ueda1], [@pone.0073683-Guo1]           430           PTEN, VEGF,STAT3,MMP-2
  miR-106b              7q22.1                  81          13-aaaagugcuuacagugcagguag-35   5 [@pone.0073683-Ding1], [@pone.0073683-Tchernitsa1], [@pone.0073683-Ueda1], [@pone.0073683-Yao1], [@pone.0073683-Guo1]          356           RB1, CDKN1A,IL-10,RUNX1
  miR-17                13q31.3                 71          14-caaagugcuuacagugcagguag-36                  4 [@pone.0073683-Oh1], [@pone.0073683-Ueda1], [@pone.0073683-Yao1], [@pone.0073683-Guo1]                          412          STAT3,ZNFX1,EIF5A2,SMAD12
  miR-18a               13q31.3                 71          6-uaaggugcaucuagugcagauag-28                   4 [@pone.0073683-Oh1], [@pone.0073683-Ueda1], [@pone.0073683-Yao1], [@pone.0073683-Guo1]                          412          DICER1,Myc,HIF1A,Eralpha
  miR-20a               13q31.3                 71          8-uaaagugcuuauagugcagguag-30                   4 [@pone.0073683-Oh1], [@pone.0073683-Ding1], [@pone.0073683-Ueda1], [@pone.0073683-Guo1]                         418          SERF1A,PKD2,SMAD12,TRPV6
  miR-19a               13q31.3                 71          14-aguuuugcauaguugcacuaca-35                              3 [@pone.0073683-Oh1], [@pone.0073683-Ueda1], [@pone.0073683-Guo1]                                     406          TNF-α,SOCS1,CCND1,TGFBR2
  miR-20b               Xq26.2                  71          6-caaagugcucauagugcagguag-28                             3 [@pone.0073683-Ding1], [@pone.0073683-Ueda1], [@pone.0073683-Guo1]                                    338           CDKN1A,MYLIP,ESR1,STAT3
  miR-25                7q22.1                  84           14-aggcggagacuugggcaauug-34                          3 [@pone.0073683-Ding1], [@pone.0073683-Tchernitsa1], [@pone.0073683-Ueda1]                                344           F8A3,FAM47C,FBXO21,LY9
  miR-18b               Xq26.2                  71          6-uaaggugcaucuagugcaguuag-28                                          2 [@pone.0073683-Oh1], [@pone.0073683-Guo1]                                                86                 Eralpha, ESR1
  miR-340               5q35.3                  95          16-uuauaaagcaaugagacugauu-37                                         2 [@pone.0073683-Yao1], [@pone.0073683-Guo1]                                                12            PELI1,PTPDC1,RNF11,SOX4
  miR-214               1q24.3                  110         30-ugccugucuacacuugcugugc -51                                     2 [@pone.0073683-Oh1], [@pone.0073683-Tchernitsa1]                                             92           BUB3,RFX3,KLF12,ARHGAP12
  miR-224                Xq28                   81           8-caagucacuagugguuccguu-28                                          2 [@pone.0073683-Oh1], [@pone.0073683-Ueda1]                                                400           API5L1,RAB9B,CXCR4,CD40
  miR-135b              1q32.1                  97          16-uauggcuuuucauuccuauguga-38                                        2 [@pone.0073683-Oh1], [@pone.0073683-Ueda1]                                                400            BGLAP,APC,RUNX2,KLF4
  miR-34a               1p36.22                 110         22-uggcagugucuuagcugguugu-43                                          2 [@pone.0073683-Oh1], [@pone.0073683-Yao1]                                                86             SIRT1,MYC,HDAC1,LEF1
  miR-125b              11q24.1                 88          15-ucccugagacccuaacuuguga-36                                      2 [@pone.0073683-Oh1], [@pone.0073683-Tchernitsa1]                                             92               p53,MUC1,VDR,IL-6
  miR-27a              19p13.13                 78          10-agggcuuagcugcuugugagca-31                                      2 [@pone.0073683-Oh1], [@pone.0073683-Tchernitsa1]                                             92            SGOL1,ZNF135,NPM1,DLEU1
  miR-103                5q34                   78          48-agcagcauuguacagggcuauga-70                                     2 [@pone.0073683-Oh1], [@pone.0073683-Tchernitsa1]                                             92            DICER1,AXIN2,HRB,ARIH2
  miR-223                Xq12                   110         26-cguguauuugacaagcugaguu-47                                          2 [@pone.0073683-Oh1], [@pone.0073683-Yao1]                                                86            GABRB3,SEMA3A,TRAPPC10
  miR-181a-2            9q33.3                  110         39-aacauucaacgcugucggugagu-61                                        2 [@pone.0073683-Ueda1], [@pone.0073683-Yao1]                                               326          p27,CDX2,BCL2,K-RAS,GATA6
  miR-92                13q31.3                 78          11-agguugggaucgguugcaaugcu-33                                    2 [@pone.0073683-Tchernitsa1], [@pone.0073683-Ueda1]                                            332            PARP2,CXCL9,SIX3,NRP2

10.1371/journal.pone.0073683.t003

###### Down-regulated miRNAs (n = 20) reported in at least two expression profiling studies.

![](pone.0073683.t003){#pone-0073683-t003-3}

  miRNAsname                                  Chromosomallocalization   Pre-miRNAlength           Mature sequence                                                          Studies(reference)                                                  Total samplesizes        Potential Target
  ------------------------------------------ ------------------------- ----------------- --------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------- ----------------------------
  miR-378                                              5q32                   66           5 -cuccugacuccagguccugugu-26     5 [@pone.0073683-Saito1], [@pone.0073683-Wang1], [@pone.0073683-Oh1], [@pone.0073683-Yao1], [@pone.0073683-Guo1]          118             CDK6, VEGF,POLH,DFFA
  miR-638                                             19p13.2                 100         16-agggaucgcgggcggguggcggccu-40              4 [@pone.0073683-Wang1], [@pone.0073683-Oh1], [@pone.0073683-Ding1], [@pone.0073683-Yao1]                      104           NKX2,CCNG2,WDR47,GPR116
  miR-30d                                             8q24.22                 70           6 -uguaaacauccccgacuggaag-27                           3 [@pone.0073683-Oh1], [@pone.0073683-Ding1], [@pone.0073683-Ueda1]                                 412              RUNX2, TP53,GNAI2
  miR-923[\*](#nt101){ref-type="table-fn"}                                                                                                        3 [@pone.0073683-Saito1], [@pone.0073683-Oh1], [@pone.0073683-Ding1]                                112         
  miR-375                                              2q35                   64           40 -uuuguucguucggcucgcguga-61                          3 [@pone.0073683-Oh1], [@pone.0073683-Ding1], [@pone.0073683-Ueda1]                                 412          JAK2,HuD, N-Cadherin,CASP3
  miR-148a                                            7p15.2                  68           6 -aaaguucugagacacuccgacu-27                        3 [@pone.0073683-Oh1], [@pone.0073683-Tchernitsa1], [@pone.0073683-Ueda1]                              412            POU2F1,BRWD1,VASH2,GSR
  miR-31                                              9p21.3                  70           8 -aggcaagaugcuggcauagcu- 28                                      2 [@pone.0073683-Wang1], [@pone.0073683-Guo1]                                            12             RHOA,FOXP3,ARPC5,CASR
  miR-133b                                            6p12.2                  119          66-uuugguccccuucaaccagcu -87                                      2 [@pone.0073683-Saito1], [@pone.0073683-Guo1]                                           26            CASP9,BCL2L2,IGF1R,PITX3
  miR-139                                             11q13.4                 68           7-ucuacagugcacgugucuccagu-29                                       2 [@pone.0073683-Oh1], [@pone.0073683-Guo1]                                             86              TMF1,FMR1,EIF4,EBF1
  miR-768[\*](#nt101){ref-type="table-fn"}                                                                                                                   2 [@pone.0073683-Saito1], [@pone.0073683-Guo1]                                           26          
  miR-141                                            12p13.31                 95           17- caucuuccaguacaguguugga-38                                     2 [@pone.0073683-Wang1], [@pone.0073683-Ding1]                                           18              CD46,EGFR,DLC1,MYOCD
  miR-663                                             17q23.2                 93           15-aggcggggcgccgcgggaccgc -36                                     2 [@pone.0073683-Wang1], [@pone.0073683-Ding1]                                           18             ZFR2,GRIN2D,PRRT1,SHOX
  miR-494                                            14q32.31                 81           48-ugaaacauacacgggaaaccuc -69                                      2 [@pone.0073683-Wang1], [@pone.0073683-Oh1]                                            88                   PTEN,CDK6,
  miR-623                                             13q32.3                 98          16- aucccuugcaggggcuguugggu-38                                      2 [@pone.0073683-Wang1], [@pone.0073683-Oh1]                                            88             IL6ST,AR,ZNF197,ACSM2A
  miR-30c                                              6q13                   70          17-uguaaacauccuacacucucagc -39                                     2 [@pone.0073683-Ding1], [@pone.0073683-Ueda1]                                           332                 MUC17,UBE2I
  miR-193b                                           16p13.12                 83          14 -cgggguuuugagggcgagauga -35                                     2 [@pone.0073683-Saito1], [@pone.0073683-Oh1]                                            100           ARL8B,CACS3,PCDH17,CCR1
  miR-939                                             8q24.3                  82          15 -uggggagcugaggcucugggggug-38                                    2 [@pone.0073683-Saito1], [@pone.0073683-Oh1]                                            100                 IL-6, TNF-α
  miR-29c                                             1q32.2                  88           16 -ugaccgauuucuccugguguuc-37                                    2 [@pone.0073683-Saito1], [@pone.0073683-Ueda1]                                           340           TCEA3,PPP2R5E,HEBP2,MAFA
  miR-30a                                              6q13                   70           6 -uguaaacauccucgacuggaag-27                                       2 [@pone.0073683-Oh1], [@pone.0073683-Ueda1]                                            400             RUNX2,MET,CDH1,WNT5A

Human mir-923 appears to be a frgament of the 28S rRNA, so is removed from the microRNA database;

Human mir-768 overlaps an annotated snoRNA, HBII-239. Phylogenetic analysis in all vertebrates supports the snoRNA annotation, with poor conservation of the reported mature miRNA sequence,it is therefore removed from the microRNA database.

10.1371/journal.pone.0073683.t004

###### The differentially expressed miRNAs (n = 9) with an inconsistent direction between studies.
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  miRNAsname    Chromosomallocalization   Pre-miRNAlength           Mature sequence           Studies(reference)   Direction ofexpression   Totalsamplesizes        Potential Target
  ------------ ------------------------- ----------------- --------------------------------- -------------------- ------------------------ ------------------ -----------------------------
  miR-106a              Xq26.2                  70           13-aaaagugcuuacagugcagguag-35            14                     ↑                     6            RB1, CDKN1A, E2F1, VEGFA
                                                                                                      9                      ↓                     80         
  miR-27a              19p13.13                 70           10 -agggcuuagcugcuugugagca-31            9                      ↑                     80          CUX1, SMAD12, PIGK, PCDHB4
                                                                                                      8                      ↓                     6          
  miR-107              10q23.31                 70          50 -agcagcauuguacagggcuauca -72           9                      ↑                     80           PLAG1, CDK6, BACE1, CRKL
                                                                                                      8                      ↓                     6          
  miR-200b              1p36.33                 94           21-caucuuacugggcagcauugga-42             9                      ↑                     80          ZNF396, RAB22A, FZD1, FLRT3
                                                                                                      8                      ↓                     6          
  miR-181c             19p13.13                 70           27 -aacauucaaccugucggugagu-48            12                     ↑                    320           IL-2, BCL-2, CDX2, GATA6
                                                                                                      9                      ↓                     80         
  miR-345               14q32.2                 98           18 -gcugacuccuaguccagggcuc-39            12                     ↑                    320             ABCC1, NTRK3, CDKN1A
                                                                                                      9                      ↓                     80         
  miR-29b               7q32.3                  80          10-gcugguuucauauggugguuuaga-33            12                     ↑                    320           USP28, LIN9, WDR26, PROS1
                                                                                                      9                      ↓                     80         
  miR-451               17q11.2                 72           17-aaaccguuaccauuacugaguu-38             12                     ↑                    320          CXCL16, CDKN2B, PSMB8, MBP
                                                                                                      9                      ↓                     80         
  miR-222               Xp11.3                  110          31-cucaguagccaguguagauccu-52             11                     ↑                     12          PTPN3, BCAR3, ADAM22,CD2AP
                                                                                                      9                      ↓                     80         

Validation of the Selected miRNAs in GC Patients {#s3c}
------------------------------------------------

To validate the expression of the six most consistently reported miRNAs (miR-21, miR-106b, miR-17, miR-18a, miR-20a and miR-378), the expression of these miRNAs in GC biopsies and adjacent noncancerous tissues were compared in 32 cases of GC using real-time PCR. The raw Ct values of the six miRNAs were shown in [Table S2](#pone.0073683.s002){ref-type="supplementary-material"}.The results showed that miR-378 was downregulated in GC tissues, whereas the other five miRNAs (miR-21, miR-106b, miR-17, miR-18a and miR-20a) were upregulated in GC ([Figure 2](#pone-0073683-g002){ref-type="fig"}). Our results were consistent with those of the original profiling studies. Furthermore, we explored the relationship between the expression of these miRNAs with the clinical and pathological features of GC. We found that the expression of miR-21 was significantly higher in cases of GC cases with larger tumor sizes (≥8 cm), poor differentiation and metastasis with lymph node involvement and later stage disease. MiR-106b, miR-17 and miR-18a levels were significantly higher in poorly differentiated GC, cases with lymph node involvement, or late stage disease, while miR-20a levels were significantly higher in cases of GC with lymph node involvement. However, no relationship was found between the expression of miR-378 and the clinicopathological features of GC. These results are detailed in [Table 5](#pone-0073683-t005){ref-type="table"}.

![Expression levels of miR-21, miR-106b, miR-17, miR-18a, miR-20a and miR-378 in GC and adjacent noncancerous tissue samples.\
Using U6 as a normalization control, the expression of miR-21, miR-106b, miR-17, miR-18a and miR-20a was significantly higher in GC tissues, while the expression of miR-378 was significantly lower.](pone.0073683.g002){#pone-0073683-g002}

10.1371/journal.pone.0073683.t005

###### The relationship between the six selected microRNAs and gastric cancer characteristics.
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                                      miR-21      miR-106b     miR-17     miR-18a    miR-20a     miR-378                                                      
  -------------------------------- ------------- ---------- ------------ --------- ------------ --------- ------------ ------ ------------ ------ ----------- ------
  **Tumor size**                                                                                                                                              
  \<8 cm                            −12.07±0.62     0.02     −1.56±0.40    0.48     −4.67±0.70    0.48     0.99±0.43    0.01   −4.46±0.59   0.41   4.06±0.31   0.84
  ≥8 cm                             −14.32±0.63              −1.94±0.33             −4.07±0.39             −0.48±0.34          −5.09±0.47          3.85±0.75  
  **Location**                                                                                                                                                
  Cardia                            −13.61±0.66     0.57     −0.97±0.50    0.18     −2.68±0.61    0.04     0.80±0.72    0.47   −4.11±0.66   0.42   5.22±1.01   0.23
  Nocardia                          −12.89±0.57              −1.90±0.29             −4.77±0.45             0.21±0.34           −4.92±0.43          3.66±0.57  
  **Lauren's classification**                                                                                                                                 
  Diffuse                           −13.37±0.70     0.43     −1.91±0.36    0.45     −4.64±0.50    0.49     0.11±0.43    0.47   −4.83±0.38   0.86   3.89±0.70   0.58
  Intestinal                        −12.61±0.65              −1.50±0.38             −4.09±0.67             0.57±0.46           −4.69±0.71          4.06±0.77  
  **Differentiation**                                                                                                                                         
  Well                              −11.68±0.68     0.02     −0.84±0.42    0.01     −3.15±0.56    0.03     1.29±0.38    0.02   −4.12±0.61   0.27   4.78±0.87   0.28
  Poor                              −13.89±0.59              −2.18±0.29             −5.01±0.49             −0.16±0.39          −5.05±0.47          3.63±0.57  
  **Metastasis with lymph node**                                                                                                                              
  No                                −11.18±1.00     0.02     −0.80±0.19    0.04     −5.37±1.30   \<0.001   1.14±0.15    0.17   −3.17±0.60   0.03   5.62±0.98   0.07
  Yes                               −13.72±0.48              −2.03±0.25             0.10±0.31              0.11±0.31           −5.21±0.40          3.29±0.55  
  **pTNM Stage**                                                                                                                                              
  Early(I+II)                       −11.62±0.75     0.02     −0.97±0.45    0.03     1.35±0.55     0.02      1.200.49    0.03   −4.22±0.56   0.31   4.31±0.74   0.63
  Later(IIII+IV)                    −13.82±0.56              −2.17±0.29             −0.19±0.33             −0.18±0.36          −5.04±0.49          3.78±0.89  

Discussion {#s4}
==========

MiRNA microarray studies provide amounts of information, but a common drawback is the lack of consistency among different studies. According to the reports of Griffith et al. and Chan et al. [@pone.0073683-Chan1], [@pone.0073683-Griffith1], a logical solution to this problem would be to determine the consistency between different studies used different microarray platforms. Several systematic reviews [@pone.0073683-Ma1]--[@pone.0073683-Griffith1] have used this method to determine differentially expressed genes or miRNAs in various disease states. Applying a similar method, we observed that a total of 48 differentially expressed miRNAs were reported in at least two independent studies among eight GC miRNA profiling studies [@pone.0073683-Saito1]--[@pone.0073683-Guo1]. Among these, 39 miRNAs were reported to be altered in a consistent direction, while the findings for nine were inconsistent. Among the 39 miRNAs that had consistent changes, 20 miRNAs were consistently upregulated in GC compared with noncancerous gastric tissue, and 19 were consistently downregulated in GC. We identified the five miRNAs that were most consistently upregulated (miR-21, miR-106a, miR-17, miR-18a and miR-20a) and two most consistently downregulated (miR-378 and miR-638) in at least four profiling studies. Then, we validated these findings using real-time PCR, which further supported the findings of this systematic review. We also determined that the expression of these miRNAs correlated with the clinicopathological features of GC, which suggested that these miRNAs may be useful as biomarkers for GC.

One of the most consistently reported upregulated miRNA in our systematic review was miR-21, which has altered expression and oncogenic activity in different human cancers. Cui et al. [@pone.0073683-Cui1] showed that the expression of miR-21 was significantly higher in GC tissue compared with adjacent normal tissue. The expression of miR-21 has also been found to be higher in patients with GC with lymph node metastasis than those without, and was also significantly correlated with the histological tumor type and pTNM stage [@pone.0073683-Xu1], which was validated by our study. Moreover, higher expression levels of miR-21 predicted poor survival in patients with GC [@pone.0073683-Xu1]. Other studies have found that miR-21 may promote tumor proliferation and invasion in GC by suppressing the expression of PTEN or PDCD4 [@pone.0073683-Zhang1], [@pone.0073683-Cao1]. Additionally, previous studies have also revealed oncogenic activity of miR-21 in colorectal cancer [@pone.0073683-Iliopoulos1], breast cancer [@pone.0073683-Han1] and esophageal cancer [@pone.0073683-Alder1].

MiR-106b was also consistently reported as an upregulated miRNA in GC tissue by this and previous studies [@pone.0073683-Guo1], [@pone.0073683-Kim1]. The high expression of miR-106b has been previously associated with lymph node metastasis [@pone.0073683-Kim1], [@pone.0073683-Tchernitsa2], and this was validated in our study. Kim et al. [@pone.0073683-Kim2] found that miR-106b may exert its oncogenic activity by suppressing p21 expression in GC. MiR-106b could induce epithelial-to-mesenchymal transition (EMT) and a tumor initiating cell phenotype in breast cancer by targeting Smad7 and Six1 and activating TGF-β signaling [@pone.0073683-Smith1]. It may also promote cell proliferation in human hepatocellular carcinoma by downregulating the expression of APC [@pone.0073683-Shen1].

MiR-17 has known oncogenic activity in humans, and was found to be upregulated in 77.2% of tissue samples of GC compared with adjacent normal gastric tissue. It promotes cell cycle progression and inhibit apoptosis in GC by targeting p21 and p53INP1 (tumor protein p53-induced nuclear protein 1) [@pone.0073683-Wang2]. Circulating levels of miR-17 are elevated in GC patients, and the concentration of miR-17 is significantly associated with the TNM stage and grade of GC [@pone.0073683-Wang3]. However, our study found that the expression of miR-17a was higher in the cases of GC without lymph node metastasis than those with lymph node involvement, which may have been a consequence of the small sample size in our study. The high expression of miR-17 is significantly correlated with poor survival outcomes [@pone.0073683-Wang3]. Previous studies have also found that miR-17 has oncogenic activity in colorectal cancer [@pone.0073683-Ma2], breast cancer [@pone.0073683-Li1] and pancreatic cancer [@pone.0073683-Yu1].

MiR-18a was found to be upregulated in four studies in this systematic review, and is known to have oncogenic activity in humans. Wu et al. [@pone.0073683-Wu1] revealed that the expression of miR-18a was significantly upregulated in GC tissue compared with normal gastric tissue, and could directly target PIAS3 (protein inhibitor of activated signal transducer and activator of transcription 3) and was positively correlated with levels of Survivin, Bcl-xl and c-myc. Moreover, the upregulation of miR-18a has been reported in nasopharyngeal carcinoma [@pone.0073683-Luo1], pancreatic cancer [@pone.0073683-Morimura1], hepatocellular carcinoma [@pone.0073683-Li2] and breast cancer [@pone.0073683-Guo2].

Mir-20a is another miRNA with oncogenic activity, and was found to be upregulated in four studies in this literature. It has been demonstrated that the circulating level of miR-20a is significantly elevated in GC patients compared to healthy controls, and this is significantly associated with the stage and grade of the tumor [@pone.0073683-Wang3], [@pone.0073683-Cai1]. Our study also found that miR-20a was significantly elevated in GC tissues and was significantly associated with lymph node metastasis. Moreover, the upregulation of miR-20a has previously been found in cervical cancer, prostate cancer and ovarian cancer, and this miRNA could promote the cell proliferation or invasion of these cancers [@pone.0073683-Kang1]--[@pone.0073683-Fan1].

The most consistently downregulated miRNA in this systematic review was miR-378, which was found to be downregulated in five studies. MiR-378 has been demonstrated to have anti-oncogenic activity in humans [@pone.0073683-Deng1]. The exogenous expression of miR-378 markedly suppresses the proliferation of GC cells by suppressing CDK6 and VEGF signaling [@pone.0073683-Deng1]. In our study, although we found that the expression of miR-378 was downregulated in GC tissues, no relationship was found between the expression of miR-378 and the clinicopathological features of GC. This may have been due to the small sample size of this study. It is also reported that miR-378 is significantly downregulated in colorectal cancer, and may play an important tumor suppressor role in this cancer [@pone.0073683-Faltejskova1]. However, other studies have found that miR-378 may have oncogenic activity in other cancer types [@pone.0073683-Wu2]--[@pone.0073683-Eichner1]. Therefore, the exact role of miR-378 in carcinogenesis needs to be further elucidated.

Furthermore, we also found that some of the candidate miRNAs identified in our study were slso identified as serum biomarkers in various cancers. For example, serum miR-21 was significantly elevated in perioperative serum from adenomas and colorectal cancer (CRC), and was an independent prognostic marker for CRC [@pone.0073683-Toiyama1], [@pone.0073683-Liu1]; Plasma miR-106b, together with miR-20a and miR-221 have the potential as novel biomarkers for early detection of gastric cancer [@pone.0073683-Cai1]; Circulating miR-17 may used as a novel noninvasive biomarker for nasopharyngeal carcinoma [@pone.0073683-Zeng1], gastric cancer [@pone.0073683-Wang4] and CRC [@pone.0073683-Faltejskova2]; Serum miR-18a may be used as a novel biomarker in breast cancer [@pone.0073683-Godfrey1], colorectal cancer [@pone.0073683-BrunetVega1], hepatocellular carcinoma [@pone.0073683-Li4], and pancreatic cancer [@pone.0073683-Morimura2]; Circulating miR-378 may be used as a biomarker in renal cell carcinoma [@pone.0073683-Redova1] and gastric cancer [@pone.0073683-Liu2]. These studies further confirmed the importance of the indentified miRNAs, and may expand the application scope of these miRNAs.

In conclusion, our systemic review identified five upregulated miRNAs (miR-21, miR-106b, miR-17, miR-18a and miR-20a) and one downregulated miRNA (miR-378) that are potential novel biomarkers for GC. These miRNAs have been shown to have diagnostic and/or prognostic potential for this cancer and warrant further investigation. Further studies that focus on these miRNAs will help to determine a panel of diagnostic and prognostic GC biomarkers with appropriate levels of sensitivity and specificity.
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